Novo Nordisk reported strong Q3 results with revenue growth driven by its obesity care, especially the Wegovy pill, offsetting declines in diabetes products. International markets outperformed the U.S., and the company achieved a 40.1% adjusted operating margin, signaling improved profitability. The firm raised its guidance, supported by robust cash flow and financial strength. Investors see potential upside with the scaling of the Wegovy pill and the upcoming 2027 launch of CagriSema.
Novo Nordisk shares are up 5.92% on Pluang, trading at USD 42.57 as of Nov 04, 2026 20:11 WIB. The stock shows strong investor interest with 90% of orders to buy and a dividend yield of 4.47%.
